US Crackdown On Foreign Biotech Investment Makes Us Poorer, Not Safer

A new US law intended primarily to curb Chinese investment is threatening the US biotechnology industry and the jobs and health benefits it brings. After passing Congress 400 to 2, the updated version of this little-known law, administered by a government committee called CFIUS, immediately triggered layoffs and reduced international fund flows into biotech companies.